This product candidate was previously licensed by Acura to King Pharmaceuticals Research and Development, a wholly owned subsidiary of King Pharmaceuticals as a result of the license, development and commercialization agreement between the companies.
Acura and King are jointly developing opioid analgesic product candidates utilizing Acura’s proprietary Aversion technology. These product candidates are intended to deter common methods of prescription drug misuse and abuse.